Citi analyst Yigal Nochomovitz lowered the firm’s price target on Crispr Therapeutics (CRSP) to $77 from $87 and keeps a Buy rating on the shares.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Promising Outlook for Crispr Therapeutics AG: Buy Rating Backed by Strong Product Launches and Strategic Developments
- CRISPR Therapeutics Reports Q3 2025 Financial Results
- FDA appoints Richard Pazdur as Director of CDER
- Crispr Therapeutics price target raised to $50 from $42 at RBC Capital
- Crispr Therapeutics price target lowered to $44 from $52 at Baird